Publications
280
Citations
11,525
Est. group size
~29
Recurring co-author estimate
Active years
30
Publishing since 1997
Typically publishes in teams of ~12 · 8% small-team papers (≤3 authors) · across 62 venues
- Prevalence and clinical characteristics of Lynch syndrome-associated adrenocortical carcinoma
Endocrine Related Cancer · 2026
- Adrenal histologic and genetic characteristics of primary aldosteronism in late adulthood
European Journal of Endocrinology · 2026
- Germline Variants in Bladder and Upper Tract Urothelial Cancers: Prevalence and Clinical Context in a Large Testing Registry
European Urology Open Science · 2026
- Adrenocortical carcinoma as a manifestation of Birt–Hogg–Dubé syndrome
Endocrine Related Cancer · 2026
- Treatment Decision Concerns: A Latent Class Analysis in Young-Onset Neuroendocrine Tumors
Endocrine Abstracts · 2026
- Distinct Sociodemographic, Symptom, and HRQoL Profiles in Early-Onset Neuroendocrine Tumors: Insights from the NET-PRO Study
Endocrine Abstracts · 2026
- Pot1-associated Melanoma: Clinical Patterns and Telomere-based Risk Assessment
Michigan Journal of Medicine · 2026
- 72058 Clinical Characterization of POT1-Associated Melanoma: A Large Single-Center Cohort Analysis
Journal of the American Academy of Dermatology · 2026
- Belzutifan for Advanced Pheochromocytoma or Paraganglioma
New England Journal of Medicine · 2025
- Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study
The Lancet Oncology · 2025
- Pathogenic Germline Variant Prevalence and Genetic Testing Outcomes in Patients With Urothelial Carcinoma
Clinical Genitourinary Cancer · 2025
- Reassessing the role of the p.(Arg304Gln) missense <i>AIP</i> variant in pituitary tumorigenesis
European Journal of Endocrinology · 2025
- Success of 177Lu-DOTATATE therapy in a metastatic pituitary neuroendocrine tumor
Endocrine Oncology · 2025
- Successful Use of Targeted HIF‐2α Inhibition in <i>EPAS1</i>‐Mutated Congenital Erythrocytosis
Pediatric Blood & Cancer · 2025
- Hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan in von Hippel-Lindau (VHL) disease–associated neoplasms: 5-year follow-up of the phase 2 LITESPARK-004 study.
Journal of Clinical Oncology · 2025
- Journal of the Endocrine Society×26
- The Journal of Clinical Endocrinology & Metabolism×13
- Journal of Clinical Oncology×11
- European Journal of Endocrinology×6
- Familial Cancer×4
- Antônio Marcondes Lerário
Medicine · University of Michigan
- Dipika R. Mohan
Medicine · University of Michigan
- Gary D. Hammer
Medicine · University of Michigan
- Katherine I. Wolf
Medicine · University of Michigan
- Lívia M. Mermejo
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile